Document Detail


The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin.
MedLine Citation:
PMID:  3571544     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The release and permeation of 1% Westragel and 1% Westrastick and three commercial 1% anthralin products were investigated in vitro with the use of a Franz diffusion cell unit. An inert Teflon membrane with a mesh opening of 74 mu was used for measuring the rate of release. Involved psoriatic and uninvolved human skin collected from the same subjects were used for the permeation study. The permeation of danthron and dianthrone, the major degradation products of anthralin, was also studied with the use of microemulsion gels of 1% danthron and 1% dianthrone, which were prepared in the same way as 1% Westragel. The penetrating anthralin, danthron, and dianthrone were stabilized by a modified receptor fluid, and sample solutions were analyzed by a high-power liquid chromatography method. Involved psoriatic skin was found to be much more permeable to anthralin than was uninvolved psoriatic skin. The slow permeation rate of anthralin, danthron, and dianthrone through normal skin and uninvolved skin indicates that the stratum corneum is the rate-limiting barrier. In involved psoriatic skin, the release rate of anthralin from the topical product becomes the rate-determining step. Large individual variations were found in the permeation of anthralin through involved psoriatic skin, suggesting that the permeation rate of anthralin also may depend on the disease state of psoriatic patients. The anthralin molecule, possessing both hydrophilic and lipophilic centers, diffused significantly faster than did danthron and dianthrone. Westragel, 1%, showed the highest diffusion rate as well as the highest driving force when compared to other commercial 1% anthralin products. This suggests that 1% Westragel may be an optimal design, especially for short-contact anthralin therapy.
Authors:
J C Wang; B G Patel; C W Ehmann; N Lowe
Related Documents :
7530014 - Dialyzer permeability for low-molecular-weight proteins. comparison between polysulfone...
11553384 - The acvd task force on canine atopic dermatitis (x): is there a relationship between ca...
2911984 - Echophonocardiography in patients undergoing percutaneous mitral balloon valvotomy (pmv...
20538034 - Konzo outbreak among refugees from central african republic in eastern region, cameroon.
24952264 - Modified sham feeding of foods with different macronutrient compositions differentially...
9020244 - A nutritional rehabilitation program for persons with severe physical and developmental...
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  16     ISSN:  0190-9622     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  1987 Apr 
Date Detail:
Created Date:  1987-06-01     Completed Date:  1987-06-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  812-21     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anthracenes / metabolism
Anthralin / metabolism*
Anthraquinones / metabolism
Humans
Psoriasis / metabolism*
Skin Absorption*
Chemical
Reg. No./Substance:
0/Anthracenes; 0/Anthraquinones; 31991-54-5/1,8,1',8'-tetrahydroxybisanthrone; 480-22-8/Anthralin; 90-44-8/anthrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Congenital pigmented and vascular lesions in newborn infants.
Next Document:  Efficacy of the Drionic unit in the treatment of hyperhidrosis.